BLOOM: behavioral modification and lorcaserin for overweight and obesity management; a 104-week, double-blind, randomized, placebo-controlled, parallel-group study to assess the safety and efficacy of lorcaserin hydrochloride in obese patients

Trial Profile

BLOOM: behavioral modification and lorcaserin for overweight and obesity management; a 104-week, double-blind, randomized, placebo-controlled, parallel-group study to assess the safety and efficacy of lorcaserin hydrochloride in obese patients

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Lorcaserin (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms BLOOM
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 13 Jun 2017 Results of post - hoc analysis of 3 trials (BLOOM, BLOSSOM, and BLOOM -DM) assessing efficacy of Lorcaserin by race presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Results of post hoc analysis of patients from BLOOM BLOSSOM, and BLOOM -DM Studies, presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 24 May 2017 Results of a cost analysis from BLOSSOM, BLOOM and BLOOM-DM studies, presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top